黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（～2026年）

• 英文タイトル：Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY12569 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,170,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬のグローバル市場について調査・分析したレポートです。種類別（黄斑変性症治療薬、糖尿病性網膜症治療薬）市場規模、用途別（50〜60歳、60〜70歳、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の競争状況、市場シェア ・世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場：種類別市場規模 2015年-2020年（黄斑変性症治療薬、糖尿病性網膜症治療薬） ・世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場：種類別市場規模予測 2021年-2026年（黄斑変性症治療薬、糖尿病性網膜症治療薬） ・世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場：用途別市場規模 2015年-2020年（50〜60歳、60〜70歳、その他） ・世界の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場：用途別市場規模予測 2021年-2026年（50〜60歳、60〜70歳、その他） ・北米の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場分析：米国、カナダ ・ヨーロッパの黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
The global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Scope and Market Size
Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan
…

Market segment by Type, the product can be split into
Macular Degeneration Drugs
Diabetic Retinopathy Drugs
Market segment by Application, split into
50-60 Years Old
60-70 Years Old
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue
1.4 Market by Type
1.4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Macular Degeneration Drugs
1.4.3 Diabetic Retinopathy Drugs
1.5 Market by Application
1.5.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application: 2020 VS 2026
1.5.2 50-60 Years Old
1.5.3 60-70 Years Old
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Perspective (2015-2026)
2.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Growth Trends by Regions
2.2.1 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Market Size
3.1.1 Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Revenue (2015-2020)
3.1.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Concentration Ratio
3.2.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue in 2019
3.3 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players Head office and Area Served
3.4 Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Solution and Service
3.5 Date of Enter into Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Historic Market Size by Type (2015-2020)
4.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)
5.2 Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
6.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in North America (2019-2020)
6.3 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
6.4 North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

7 Europe
7.1 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
7.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in Europe (2019-2020)
7.3 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
7.4 Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

8 China
8.1 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
8.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in China (2019-2020)
8.3 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
8.4 China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

9 Japan
9.1 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
9.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in Japan (2019-2020)
9.3 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
9.4 Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
10.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

11 India
11.1 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
11.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in India (2019-2020)
11.3 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
11.4 India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size (2015-2020)
12.2 Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020)
12.4 Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.1.4 Novartis Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Bayer Healthcare
13.2.1 Bayer Healthcare Company Details
13.2.2 Bayer Healthcare Business Overview
13.2.3 Bayer Healthcare Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.2.4 Bayer Healthcare Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020)
13.2.5 Bayer Healthcare Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.3.4 Roche Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Neurotech Pharmaceuticals
13.4.1 Neurotech Pharmaceuticals Company Details
13.4.2 Neurotech Pharmaceuticals Business Overview
13.4.3 Neurotech Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.4.4 Neurotech Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020)
13.4.5 Neurotech Pharmaceuticals Recent Development
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Details
13.5.2 Regeneron Pharmaceuticals Business Overview
13.5.3 Regeneron Pharmaceuticals Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.5.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020)
13.5.5 Regeneron Pharmaceuticals Recent Development
13.6 Allergan
13.6.1 Allergan Company Details
13.6.2 Allergan Business Overview
13.6.3 Allergan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Introduction
13.6.4 Allergan Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020)
13.6.5 Allergan Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue
Table 3. Ranking of Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Macular Degeneration Drugs
Table 6. Key Players of Diabetic Retinopathy Drugs
Table 7. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2015-2020)
Table 11. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Growth Strategy
Table 17. Main Points Interviewed from Key Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players
Table 18. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue by Players (2015-2020) (Million US$)
Table 19. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Players (2015-2020)
Table 20. Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs as of 2019)
Table 21. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Product Solution and Service
Table 24. Date of Enter into Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 27. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Share by Type (2015-2020)
Table 28. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue Market Share by Type (2021-2026)
Table 29. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Share by Application (2015-2020)
Table 30. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 31. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size Share by Application (2021-2026)
Table 32. North America Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 34. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 35. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 36. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 37. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 38. Europe Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 40. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 42. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 44. China Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 45. China Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 46. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 48. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 50. Japan Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 52. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 54. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 58. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 60. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 62. India Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 63. India Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 64. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 66. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share (2019-2020)
Table 70. Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type (2015-2020)
Table 72. Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application (2015-2020)
Table 74. Novartis Company Details
Table 75. Novartis Business Overview
Table 76. Novartis Product
Table 77. Novartis Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 78. Novartis Recent Development
Table 79. Bayer Healthcare Company Details
Table 80. Bayer Healthcare Business Overview
Table 81. Bayer Healthcare Product
Table 82. Bayer Healthcare Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 83. Bayer Healthcare Recent Development
Table 84. Roche Company Details
Table 85. Roche Business Overview
Table 86. Roche Product
Table 87. Roche Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 88. Roche Recent Development
Table 89. Neurotech Pharmaceuticals Company Details
Table 90. Neurotech Pharmaceuticals Business Overview
Table 91. Neurotech Pharmaceuticals Product
Table 92. Neurotech Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 93. Neurotech Pharmaceuticals Recent Development
Table 94. Regeneron Pharmaceuticals Company Details
Table 95. Regeneron Pharmaceuticals Business Overview
Table 96. Regeneron Pharmaceuticals Product
Table 97. Regeneron Pharmaceuticals Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 98. Regeneron Pharmaceuticals Recent Development
Table 99. Allergan Company Details
Table 100. Allergan Business Overview
Table 101. Allergan Product
Table 102. Allergan Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Business (2015-2020) (Million US$)
Table 103. Allergan Recent Development
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Type: 2020 VS 2026
Figure 2. Macular Degeneration Drugs Features
Figure 3. Diabetic Retinopathy Drugs Features
Figure 4. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Application: 2020 VS 2026
Figure 5. 50-60 Years Old Case Studies
Figure 6. 60-70 Years Old Case Studies
Figure 7. Other Case Studies
Figure 8. Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Report Years Considered
Figure 9. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Share by Players in 2019
Figure 14. Global Top Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Revenue in 2019
Figure 16. North America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed

---